FR2850970B1 - CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT - Google Patents

CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT

Info

Publication number
FR2850970B1
FR2850970B1 FR0301478A FR0301478A FR2850970B1 FR 2850970 B1 FR2850970 B1 FR 2850970B1 FR 0301478 A FR0301478 A FR 0301478A FR 0301478 A FR0301478 A FR 0301478A FR 2850970 B1 FR2850970 B1 FR 2850970B1
Authority
FR
France
Prior art keywords
specific
application
anticancer agent
chemical derivatives
dna structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0301478A
Other languages
French (fr)
Other versions
FR2850970A1 (en
Inventor
Augustin Hittinger
Thomas Caulfield
Patrick Maillet
Herve Bouchard
Eliane Mandine
Chafke Belmokhtar
Jean Louis Mergny
Lionel Guittat
Jean Francois Riou
Dennis Gomez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Aventis Pharma SA
Institut Curie
Museum National dHistoire Naturelle
Universite de Reims Champagne Ardenne URCA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Aventis Pharma SA
Institut Curie
Museum National dHistoire Naturelle
Universite de Reims Champagne Ardenne URCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0301478A priority Critical patent/FR2850970B1/en
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Aventis Pharma SA, Institut Curie, Museum National dHistoire Naturelle, Universite de Reims Champagne Ardenne URCA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU2004210753A priority patent/AU2004210753A1/en
Priority to PCT/FR2004/000260 priority patent/WO2004072027A2/en
Priority to EP04708378A priority patent/EP1603898A2/en
Priority to CA002514105A priority patent/CA2514105A1/en
Priority to BRPI0407320-7A priority patent/BRPI0407320A/en
Priority to JP2006502131A priority patent/JP2006518726A/en
Priority to MXPA05007648A priority patent/MXPA05007648A/en
Priority to US10/773,806 priority patent/US20070232572A1/en
Publication of FR2850970A1 publication Critical patent/FR2850970A1/en
Application granted granted Critical
Publication of FR2850970B1 publication Critical patent/FR2850970B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
FR0301478A 2003-02-07 2003-02-07 CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT Expired - Fee Related FR2850970B1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (en) 2003-02-07 2003-02-07 CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT
PCT/FR2004/000260 WO2004072027A2 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent
EP04708378A EP1603898A2 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent
CA002514105A CA2514105A1 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent
AU2004210753A AU2004210753A1 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent
BRPI0407320-7A BRPI0407320A (en) 2003-02-07 2004-02-05 chemical derivatives that bind very specifically to g-quadruple DNA structures and their application as a specific anticancer agent
JP2006502131A JP2006518726A (en) 2003-02-07 2004-02-05 Chemical derivatives that bind very specifically to G-quadruplex DNA structures and their use as specific anti-cancer agents
MXPA05007648A MXPA05007648A (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent.
US10/773,806 US20070232572A1 (en) 2003-02-07 2004-02-06 Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (en) 2003-02-07 2003-02-07 CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT

Publications (2)

Publication Number Publication Date
FR2850970A1 FR2850970A1 (en) 2004-08-13
FR2850970B1 true FR2850970B1 (en) 2006-07-07

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0301478A Expired - Fee Related FR2850970B1 (en) 2003-02-07 2003-02-07 CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT

Country Status (8)

Country Link
EP (1) EP1603898A2 (en)
JP (1) JP2006518726A (en)
AU (1) AU2004210753A1 (en)
BR (1) BRPI0407320A (en)
CA (1) CA2514105A1 (en)
FR (1) FR2850970B1 (en)
MX (1) MXPA05007648A (en)
WO (1) WO2004072027A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
WO2008032324A2 (en) * 2006-09-14 2008-03-20 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
CN101889210B (en) 2008-05-27 2014-12-10 松下电器产业株式会社 G-quadruplex detection method, G-quadruplex DNA detection method, and telomerase activity measurement method
JP4510929B1 (en) 2009-04-09 2010-07-28 パナソニック株式会社 Telomerase reaction inhibition method and telomerase reaction inhibitor used therefor
CN108066341B (en) * 2016-11-10 2020-10-30 中国科学院化学研究所 Application of compound in preparation of anti-cancer drugs
CN108066340B (en) * 2016-11-10 2020-10-27 中国科学院化学研究所 Pharmaceutical composition
WO2018211148A1 (en) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Bisquinolium derivatives for preventing or treating ebv-related cancers
CN113272294A (en) * 2018-08-24 2021-08-17 雅典学院生物医学研究基金会 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200263A (en) * 1999-11-29 2003-06-16 Aventis Pharma S.A. G-quadruplex structure fixing compounds of telomers, their use and therapeutic combinations
FR2819255B1 (en) * 2001-01-09 2003-02-28 Aventis Pharma Sa CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
FR2821355A1 (en) * 2001-02-23 2002-08-30 Aventis Pharma Sa CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
CO5380035A1 (en) * 2001-03-23 2004-03-31 Aventis Pharma Sa CHEMICAL DERIVATIVES AND THEIR APPLICATION AS AN ANTITELOMERASA AGENT
JP2004534046A (en) * 2001-05-28 2004-11-11 アベンティス・ファーマ・ソシエテ・アノニム Chemical derivatives and their use as anti-telomerase agents

Also Published As

Publication number Publication date
AU2004210753A1 (en) 2004-08-26
JP2006518726A (en) 2006-08-17
WO2004072027A2 (en) 2004-08-26
CA2514105A1 (en) 2004-08-26
EP1603898A2 (en) 2005-12-14
MXPA05007648A (en) 2006-12-15
FR2850970A1 (en) 2004-08-13
BRPI0407320A (en) 2006-02-21
WO2004072027A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
DK2821085T3 (en) RNA INTERFERENCE TO TREAT GAIN-OF-FUNCTION DISORDERS
IL237721B (en) Nucleic acid-lipid particles comprising interfering rna, compositions comprising same and uses thereof
AP2328A (en) Synthetic compounds useful as nodulation agents ofleguminous plants and preparation processes thereof.
TWI347184B (en) Methods of treating hiv infection
FR2850970B1 (en) CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT
WO2004089947A3 (en) Novel compounds having an antibacterial activity
HK1054967A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
DE60121878D1 (en) Microactuator and its production process
PL2295549T3 (en) Nicotiana nucleic acid molecules and uses thereof
EP1633871A4 (en) Double-stranded nucleic acid
DE60108042D1 (en) Processes for the production of powdered impact modifiers
MA29015B1 (en) SPECIFIC BINDING AGENTS OF ANGIOPOIETIN-2
EP1927587A3 (en) Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
FR2884244B1 (en) OBTAINING AMMONIUM DINITROAMIDIDE CRYSTALS (DNA); DNA CRYSTALS AND ENERGY COMPOSITES CONTAINING THEM.
EP1667999A4 (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
GB0608813D0 (en) Improved methods and compositions for RNA interference
DE60211579D1 (en) Filter and its production process
FR2855374B1 (en) IMPROVED HARD DRAGEING PROCESS
EP1628993A4 (en) Methods and compositions for rna interference
PT1603550E (en) Pharmaceutical composition comprising 5-methyl-2-2`-(chloro-6`-fluoroanilino)phenylacetic acid
ZA200610141B (en) Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
GB0328497D0 (en) Compounds which bind to the active site of protein kinase enzymes
MA28161A1 (en) Pentafluorosulfanylbenzoylguanidines, process for their production, their use as medicaments or diagnostic agents and medicaments containing them
GB0311804D0 (en) Improved homocysteine assay
AU2003901647A0 (en) Novel Condensed Furan Compounds and Pharmaceutical Use Thereof

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101029